BioSpace News Archive

Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co, a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters through its subsidiary Pharma Tech Solutions, Inc., today announced it is finalizing its Covid-19 Saliva Swift Kits for international use along with its recommended pricing for the global market.

Laparoscopy is a diagnostic procedure used to observe the abdominal section of a body.

Vifor Pharma has announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd.

160 patient balstilimab (PD-1) monotherapy trial achieves response rates of 14% in all treated patients and 19% in PD-L1 positive patients

HER3 directed ADC demonstrates clinical activity in patients with EGFR-mutated metastatic or unresectable NSCLC previously treated with a tyrosine kinase inhibitor and platinum-based chemotherapy in first presentation of dose expansion data for patritumab deruxtecan

5-Year Data from Phase 3 SOLO-1 Trial Represents Longest Follow-Up Analysis for Any PARP Inhibitor in First-Line Maintenance Setting Following Response to Platinum-Based Chemotherapy

OncXerna’s RNA-based biomarker platform successfully identified responders versus non-responders in trials with late-stage cancer patients

Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the appointment of pharmaceutical industry leader Michael Kamarck, Ph.D., to its Board of Directors, effective immediately.

Renalytix AI plc, an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the commercial launch of the KidneyIntelX clinical test reporting platform within the Mount Sinai Health System in New York City.

PACIFIC Phase III trial data at ESMO also showed an estimated 35% of non-small cell lung cancer patients treated with IMFINZI® had not progressed after four years